Breaking News Instant updates and real-time market news.

ABX

Barrick Gold

$15.84

0.385 (2.49%)

, NCLH

Norwegian Cruise Line

$38.05

0.27 (0.71%)

10:16
10/05/16
10/05
10:16
10/05/16
10:16

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Barrick Gold (ABX) downgraded to Buy from Conviction Buy at Goldman with analyst Andrew Quail citing increased macro headwinds negatively impacting gold prices. 2. Norwegian Cruise Line (NCLH) downgraded to Neutral from Buy at UBS. 3. Gigamon (GIMO) downgraded to Market Perform from Outperform at Raymond James and to Neutral from Buy at DA Davidson. 4. iRadimed (IRMD) downgraded to Neutral from Buy at Roth Capital. 5. Trinity Biotech (TRIB) downgraded to Equal Weight from Overweight at Stephens with analyst Drew Jones citing the announcement of the withdrawal of Meritas Troponin test from FDA consideration. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ABX

Barrick Gold

$15.84

0.385 (2.49%)

NCLH

Norwegian Cruise Line

$38.05

0.27 (0.71%)

GIMO

Gigamon

$52.32

-2.81 (-5.10%)

IRMD

iRadimed

$10.77

-6.24 (-36.68%)

TRIB

Trinity Biotech

$6.46

-6.53 (-50.27%)

  • 27

    Oct

ABX Barrick Gold
$15.84

0.385 (2.49%)

10/05/16
GSCO
10/05/16
DOWNGRADE
Target $27
GSCO
Buy
Barrick Gold downgraded to Buy from Conviction Buy at Goldman
Goldman analyst Andrew Quail removed Barrick Gold from the Conviction Buy List to reflect increased macro headwinds negatively impacting gold prices. The analyst maintains his Buy rating and $27 price target and said its self-help story remains intact.
10/03/16
10/03/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dow Chemical (DOW) and DuPont (DD) were upgraded to Buy from Neutral at Citi with analyst P.J. Juvekar citing he opportunity presented by the proposed merger. 2. Freeport McMoRan (FCX), Barrick Gold (ABX), and Pan American Silver (PAAS) were upgraded to Buy from Hold at Deutsche Bank. 3. LogMeln (LOGM) upgraded to Overweight from Equal Weight at Barclays with analyst Raimo Lenschow saying the pending merger with Citrix's (CTXS) divested GoTo assets creates a "great new opportunity." 4. Halliburton (HAL) upgraded to Buy from Hold at Societe General. 5. Coty (COTY) upgraded to Buy from Neutral at BofA/Merrill with analyst Olivia Tong saying she believes Coty is at the beginning of a potential transformation with the pending closure of the P&G Beauty deal this week that could bring increased scale as well as a more targeted operational structure. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
DBAB
10/03/16
UPGRADE
DBAB
Buy
Barrick, Freeport, Pan American upgraded to Buy at Deutsche Bank
Deutsche Bank analyst Jorge Beristain noted that while commodity prices rallied in Q3 Metals & Mining companies continued to get their "financial houses in order" and he expects the trend to continue for the next few quarters. The analyst, who recommends investing in non-integrated companies as well as building Precious exposure, is upgrading several stocks in the sector, including Barrick Gold (ABX), Freeport McMoRan (FCX), Pan American Silver (PAAS), all to Buy from Hold. The analyst also upgraded a number of others in the sector to Hold from Sell this morning.
10/03/16
DBAB
10/03/16
UPGRADE
DBAB
Buy
Barrick Gold upgraded to Buy from Hold at Deutsche Bank
NCLH Norwegian Cruise Line
$38.05

0.27 (0.71%)

10/05/16
UBSW
10/05/16
DOWNGRADE
Target $42
UBSW
Neutral
Norwegian Cruise Line downgraded to Neutral from Buy at UBS
UBS analyst Robin Farley downgraded Norwegian Cruise Line to Neutral and lowered her price target for the shares to $42 from $54.
10/04/16
10/04/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. ACADIA (ACAD) reinstated with a Market Perform at Leerink. 2. Royal Caribbean (RCL) was initiated with an Outperform at Macquarie, while the firm initiated Carnival (CCL) and Norwegian Cruise Line (NCLH) with a Neutral. 3. Shopify (SHOP) initiated with a Buy at Goldman. 4. Dolby (DLB) assumed with a Neutral at JPMorgan. 5. United Rentals (URI) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/16
MACQ
10/04/16
INITIATION
Target $37.7
MACQ
Neutral
Norwegian Cruise Line initiated with a Neutral at Macquarie
Macquarie analyst Matthew Brooks initiated Carnival with a Neutral and a $37.70 price target given high financial leverage, senior management turnover, and high valuation.
09/29/16
DBAB
09/29/16
NO CHANGE
Target $44
DBAB
Hold
Norwegian Cruise Line transferred with a Hold at Deutsche Bank
Deutsche Bank analyst Chris Woronka put a Hold rating and $44 price target on shares of Norwegian Cruise Line after taking over coverage of the name. Cautious investor sentiment and industry capacity concerns are likely to limit near-term upside in the cruise line space, Woronka tells investors in a research note.
GIMO Gigamon
$52.32

-2.81 (-5.10%)

10/05/16
RAJA
10/05/16
DOWNGRADE
RAJA
Market Perform
Gigamon downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Simon Leopold downgraded Gigamon to Market Perform citing valuation and concerns over slowing in the security market. Potential upside from the company's new hybrid cloud solution will take time to materialize, Leopold tells investors in a research note. He believes Gigamon remains a growth story, but finds the stock fairly valued at current levels.
09/14/16
WBLR
09/14/16
NO CHANGE
WBLR
Outperform
Gigamon business momentum remains strong, says William Blair
After hosting investor meetings with Gigamon CEO Paul Hooper, William Blair analyst Jason Ader believes the company's business momentum "remains strong and unyielding." Street expectations have Gigamon's top-line growth decelerating to 20% in 2017 from 40% in 2016, which creates "meaningful opportunity for upside," Ader tells investors in a research note. He keeps an Outperform rating on the shares.
10/05/16
DADA
10/05/16
DOWNGRADE
DADA
Neutral
Gigamon downgraded to Neutral from Buy at DA Davidson
10/05/16
DADA
10/05/16
DOWNGRADE
Target $59
DADA
Neutral
Gigamon downgraded to Neutral on valuation at DA Davidson
As previously reported, DA Davidson downgraded Gigamon to Neutral from Buy. Analyst Mark Kelleher reduced his rating due to valuation and raised his price target to $59 from $54 on shares. Note that Gigamon was also downgraded at Raymond James this morning to Market Perform.
IRMD iRadimed
$10.77

-6.24 (-36.68%)

01/28/16
ROTH
01/28/16
NO CHANGE
ROTH
iRadimed should be bought on weakness, says Roth Capital
Noting that iRadimed's stock has dropped about 25% after it reported higher than expected preliminary Q4 revenue on January 11, Roth Capital thinks that the company's fundamentals remain strong, while its 2016 results will probably exceed its guidance. The firm thinks the sell-off i nthe stock is overdone and it keeps a $30 price target and Buy rating on the shares.
04/04/16
ROTH
04/04/16
NO CHANGE
Target $25
ROTH
Buy
iRadimed price target lowered to $25 from $30 at Roth Capital
Roth Capital analyst Chris Lewis lowered his price target for iRadimed to $25 from $30 to reflect increased regulatory uncertainty. The FDA has denied approval for the company's 510k application for its MRI compatible infusion pump, with iRadimed planning to appeal the decision, the analyst tells investors in a research note. Lewis says the company will continue selling its pump systems domestically while it continues efforts to obtain new FDA clearance. The analyst reiterates a Buy rating on the shares.
10/05/16
ROTH
10/05/16
DOWNGRADE
Target $11.5
ROTH
Neutral
iRadimed downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Chris Lewis downgraded iRadimed to Neutral from Buy after the company pre-announced a Q3 miss and reduced its 2016 outlook. While still a believer in iRadimed's technologies and market opportunity over the longer-term, the analyst will look for sales cycle normalization, improving new order activity, margin visibility, and MRI-monitor regulatory progress/commercial launch to gain higher conviction. He also lowered his price target on the shares to $11.50 from $28.
06/09/16
ROTH
06/09/16
NO CHANGE
Target $28
ROTH
Buy
Roth Capital sees new regulatory development as positive for iRadimed
Roth Capital analyst Chris Lewis says the FDA has accepted iRadimed 's 510k denial appeal pending certain requests related to software message display changes and will not require additional human factors usability testing. The analyst sees the news as a positive regulatory development for the company and more favorable than his previous expectations. Lewis reiterates a Buy rating on the stock and raised his price target on the shares to $28 from $25 on the improved regulatory outlook.
TRIB Trinity Biotech
$6.46

-6.53 (-50.27%)

10/05/16
10/05/16
DOWNGRADE
Target $7

Equal Weight
Trinity Biotech downgraded to Equal Weight at Stephens
As previously reported, Stephens analyst Drew Jones downgraded Trinity Biotech to Equal Weight from Overweight following the announcement of the withdrawal of Meritas Troponin test from FDA consideration. While the company is not abandoning the Meritas technology, the analyst notes that he currently has limited visibility into how the program will be progressed. Jones also remains conservative with expectations of Trinity Biotech successfully turning into an EPS growth story. He lowered his price target on the shares to $7 from $22.
03/04/16
SPHN
03/04/16
NO CHANGE
Target $22
SPHN
Overweight
Trinity Biotech remains top Diagnostics/Life Science Tools idea at Stephens
Stephens analyst Drew Jones said Trinity Biotech remains his favorite idea in the Diagnostics/Life Science Tools space for 2016 in a post-earnings research note. The company second straight quarter of matching consensus earnings expectations has re-established "some much needed credibility" on its execution, according to Jones, looks for an acceleration in organic growth this year. The analyst keeps an Overweight rating and $22 price target on Trinity shares.
10/05/16
SPHN
10/05/16
DOWNGRADE
SPHN
Equal Weight
Trinity Biotech downgraded to Equal Weight from Overweight at Stephens
04/21/16
ROTH
04/21/16
NO CHANGE
Target $13
ROTH
Buy
Roth Capital remains bullish on long-term Trinity Biotech troponin opportunity
Roth Capital analyst Chris Lewis remains bullish on the long-term Trinity Biotech's troponin opportunity, after the company received the FDA's formal response for its troponin 510k submission, which does not request any extensive additional data. However, the analyst looks for improved underlying growth and profitability trends to materialize to gain higher near-term conviction on the name. Lewis reiterates a Buy rating and $13 price target on the shares.

TODAY'S FREE FLY STORIES

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

13:26
06/23/17
06/23
13:26
06/23/17
13:26
Hot Stocks
Portola Pharmaceuticals to resume trading at 1:35 pm ET »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

CHGG

Chegg

$12.44

0.48 (4.01%)

13:25
06/23/17
06/23
13:25
06/23/17
13:25
Recommendations
Chegg analyst commentary  »

Chegg price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
06/23/17
06/23
13:25
06/23/17
13:25
General news
Energy Action: Baker-Hughes »

Energy Action:…

VRX

Valeant

$15.58

0.0801 (0.52%)

13:20
06/23/17
06/23
13:20
06/23/17
13:20
Options
Valeant expiring options active Friday »

Valeant expiring options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

$NSD

NASDAQ Market Internals

13:17
06/23/17
06/23
13:17
06/23/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
06/23/17
06/23
13:16
06/23/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLLS

Cellectis

$23.15

0.25 (1.09%)

13:15
06/23/17
06/23
13:15
06/23/17
13:15
Hot Stocks
Breaking Hot Stocks news story on Cellectis 

Cellectis trading resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

INFY

Infosys

$14.90

0.13 (0.88%)

13:13
06/23/17
06/23
13:13
06/23/17
13:13
Hot Stocks
Infosys says 'committed no wrongdoing, denies all allegations' in NY tax matter »

Infosys issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLLS

Cellectis

$23.15

0.25 (1.09%)

13:08
06/23/17
06/23
13:08
06/23/17
13:08
Hot Stocks
Cellectis to resume trading at 1:15 pm ET »

Cellectis is scheduled to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

13:06
06/23/17
06/23
13:06
06/23/17
13:06
Hot Stocks
Portola Pharmaceuticals announces FDA approval of Bevyxxa »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

TRIP

TripAdvisor

$35.74

-0.08 (-0.22%)

13:05
06/23/17
06/23
13:05
06/23/17
13:05
Options
TripAdvisor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:05
06/23/17
06/23
13:05
06/23/17
13:05
General news
Cleveland Fed hawk Mester didn't discuss policy »

Cleveland Fed hawk Mester…

BHI

Baker Hughes

$54.55

0.025 (0.05%)

13:03
06/23/17
06/23
13:03
06/23/17
13:03
Hot Stocks
Baker Hughes reports U.S. rig count up 8 to 941 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:00
06/23/17
06/23
13:00
06/23/17
13:00
General news
Treasury Action: upcoming supply should put a floor under short rates »

Treasury Action: upcoming…

RIO

Rio Tinto

$39.32

0.61 (1.58%)

, GLNCY

Glencore

$7.10

0.05 (0.71%)

12:59
06/23/17
06/23
12:59
06/23/17
12:59
Hot Stocks
Rio Tinto to give new Glencore C&A proposal 'appropriate consideration' »

Rio Tinto (RIO)…

RIO

Rio Tinto

$39.32

0.61 (1.58%)

GLNCY

Glencore

$7.10

0.05 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLLS

Cellectis

$23.15

0.25 (1.09%)

12:56
06/23/17
06/23
12:56
06/23/17
12:56
Hot Stocks
Cellectis announces Calyxt filing of registration statement for proposed IPO »

Cellectis S.A. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

PX

Praxair

$133.62

1.15 (0.87%)

12:50
06/23/17
06/23
12:50
06/23/17
12:50
Options
Call spread in Praxair may add to existing bullish position »

Call spread in Praxair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYT

Syngenta

$92.65

0.05 (0.05%)

12:45
06/23/17
06/23
12:45
06/23/17
12:45
Periodicals
Syngenta ordered to pay $217.7M to Kansas farmers in GMO corn case, Reuters says »

A federal jury in Kansas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MT

ArcelorMittal

$21.21

0.315 (1.51%)

12:45
06/23/17
06/23
12:45
06/23/17
12:45
Options
ArcelorMittal call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
06/23/17
06/23
12:45
06/23/17
12:45
General news
Breaking General news story  »

Week of 6/23 Baker-Hughes…

EFA

iShares MSCI EAFE Index Fund

$65.14

0.16 (0.25%)

, VEA

Vanguard Europe Pacific ETF

$41.22

0.089 (0.22%)

12:42
06/23/17
06/23
12:42
06/23/17
12:42
Technical Analysis
On The Fly: ETF fund flow highlights »

For the past week there…

EFA

iShares MSCI EAFE Index Fund

$65.14

0.16 (0.25%)

VEA

Vanguard Europe Pacific ETF

$41.22

0.089 (0.22%)

IEFA

iShares Core MSCI EAFE ETF

$60.83

0.135 (0.22%)

EWJ

iShares MSCI Japan Index Fund

$54.04

-0.05 (-0.09%)

EZU

iShares MSCI Eurozone ETF

$40.44

0.1 (0.25%)

IBB

iShares Nasdaq Biotechnology Index

$320.11

4.01 (1.27%)

IVV

iShares Core S&P 500

$246.13

0.53 (0.22%)

SPY

SPDR S&P 500 ETF Trust

$243.37

0.53 (0.22%)

VO

Vanguard Mid-Cap Index Fund

$143.23

0.561 (0.39%)

VTI

Vanguard Total Stock Market ETF

$125.10

0.36 (0.29%)

VUG

Vanguard Growth Index Fund

$128.93

0.421 (0.33%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.11

0.265 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

12:33
06/23/17
06/23
12:33
06/23/17
12:33
Hot Stocks
Portola FDA label cites secondary endpoint instead of Cohort 1 data, tweet says »

Twitter user…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

VIX

Volatility Index S&P 500 Options

12:30
06/23/17
06/23
12:30
06/23/17
12:30
Options
VIX calls outpace puts nearly 5:1 as the index dips below 10 »

VIX calls outpace puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.55

0.2 (1.62%)

, CACQ

Caesars Acquisition

$19.40

0.15 (0.78%)

12:29
06/23/17
06/23
12:29
06/23/17
12:29
Hot Stocks
Caesars announces effectiveness of S-4 registration statement related to merger »

Caesars Entertainment…

CZR

Caesars

$12.55

0.2 (1.62%)

CACQ

Caesars Acquisition

$19.40

0.15 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLYC

GlycoMimetics

$12.10

-0.03 (-0.25%)

12:28
06/23/17
06/23
12:28
06/23/17
12:28
Conference/Events
GlycoMimetics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.